,0,1,2,3,4,5,6
0,Therapy,Consecutive,Diagnosis,Therapy,Duration of,,
1,group,patient number,Diagnosis,Therapy,therapy (weeks),Supportive therapy,
2,Group A,21,SCLC,"Carboplatin, etoposid",16.3,,
3,,2,NSCLC,"Carboplatin, gemcitabin",15.1,IrRBC,+
4,,12,NSCLC,"Carboplatin, paclitaxel",20.1,"IrRBC,EPO",
5,,3,NSCLC,"Carboplatin,paclitaxel",19.0,IrRBC,
6,,13,NSCLC,"Carboplatin,paclitaxel",12.7,-,
7,,16,NSCLC,"Carboplatin, paclitaxel",12.0,,
8,,18,NSCLC,"Carboplatin, paclitaxel",15.0,-,
9,,19,NSCLC,"Carboplatin, paclitaxel",13.0,,
10,,15,NSCLC,"Carboplatin,paclitaxel,atezolizumab",29.1,EPO,
11,,5,NSCLC,"Carboplatin,paclitaxel,atezolizumab",12.4,"IrRBC,EPO",
12,,8,NSCLC,"Carboplatin,paclitaxel,atezolizumab",20.4,"IrRBC,EPO",
13,,4,NSCLC,"Carboplatin, paclitaxel, atezolizumab",19.0,,
14,,9,NSCLC,"Carboplatin, paclitaxel, atezolizumab",16.0,,
15,,14,NSCLC,"Carboplatin,paclitaxel,atezolizumab",17.4,-,
16,,22,NSCLC,"Carboplatin, pemetrexed",15.0,IrRBC,
17,,6,NSCLC,"Carboplatin, pemetrexed",10.1,"IrRBC,GCSF",
18,,7,NSCLC,"Carboplatin, pemetrexed",15.0,,+
19,,10,NSCLC,"Carboplatin, pemetrexed",15.1,,
20,,11,NSCLC,"Carboplatin, pemetrexed",16.4,,
21,,25,NSCLC,"Carboplatin,pemetrexed",15.0,1,
22,,26,NSCLC,"Carboplatin, pemetrexed, pembrolizumab",14.0,,
23,,1,SCLC,"Cisplatin, etoposid",15.9,-,
24,Group B,17,NSCLC,Afatinib,50.9,,
25,,29,NSCLC,Crizotinib,29.7,,
26,,27,NSCLC,"Dabrafenib,trametinib",33.3,,
27,,28,NSCLC,Osimertinib,28.1,,
28,,30,NSCLC,Osimertinib,27.7,,
29,,20,NSCLC,Pembrolizumab,91.6,,
30,,23,NSCLC,Pembrolizumab,44.6,-,
31,,24,NSCLC,Pembrolizumab,23.0,,
32,,31,NSCLC,Pembrolizumab,10.3,-,
